E
Edgewise Therapeutics Inc (EWTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$42.04
-1.64 (-3.75%)
Market Cap: $5.03B
Last updated: Nov 17, 2026 at 4:20 PM ET
Edgewise Therapeutics Inc (EWTX) Valuation Multiples
Edgewise Therapeutics (EWTX) trades at 2.8x book value. Its P/B of 2.8x is in line with its 5-year median. Its forward P/E is 63.1x.
Current Multiples
Its enterprise value is 4.0x its EBITDA.
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 63.1x |
| Price to book | 2.8x |
| EV/EBITDA | 4.0x |
| PEG | N/A |
| FCF yield | -4.4% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/B | 2.8x | 2.8x | N/A |
Valuation History
Over the 5 year ends shown, its P/B ranged from 1.6x in 2022 to 5.4x in 2024.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $24.82 | N/A | 4.9x |
| 2024 | $26.70 | N/A | 5.4x |
| 2023 | $10.94 | 314.7x | 2.2x |
| 2022 | $8.94 | N/A | 1.6x |
| 2021 | $15.28 | N/A | 2.7x |
Frequently Asked Questions About EWTX
What is EWTX's forward P/E ratio?
Edgewise Therapeutics has a forward P/E ratio of 63.1x.
EWTX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors